Retevmo TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: selpercatinib
Brand name
(ARTG)
: RETEVMO selpercatinib 80 mg immediate release capsulesDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
RETEVMO has provisional approval for the treatment of adult patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer (NSCLC).,The decision to approve this indication has been made on the basis of objective response rate (ORR) and duration of response (DOR) from a single arm study. Continued approval of this indication depends on verification and description of benefit in a confirmatory trial.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Capsule, hard
- Oral
- Blue opaque capsule imprinted with Lilly 2980 and 80 mg in black ink.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 112 pack
- 14 pack
- 28 pack
- 56 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient selpercatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
